Candel's Aglatimagene Shows Prolonged Survival In Phase 2a NSCLC Trial

Candel Therapeutics reported final Phase 2a data for aglatimagene besadenovec plus valacyclovir in unresectable Stage III/IV non-small cell lung cancer patients who had responded inadequately to immune checkpoint inhibitors. The article provides no efficacy, safety, or statistical results, limiting assessment of the program's clinical significance; however, final Phase 2a data could affect CADL shares depending on the underlying readout.